title: Pulmonary arterial hypertension: thin-section CT predictors of epoprostenol therapy failure.
abstract: OBJECTIVE
  To correlate pretherapeutic thin-section computed tomographic (CT) findings in patients with pulmonary hypertension with the risk of fatality with treatment with epoprostenol.
  
  
  METHODS
  Seventy-three consecutive patients with severe pulmonary hypertension treated with epoprostenol were retrospectively separated into two groups. The first group included 12 patients who had a fatal outcome with epoprostenol therapy. The second group (n = 61) was a reference group of patients with epoprostenol-induced clinical improvement. Pretherapeutic thin-section CT scans of each patient were reviewed.
  
  
  RESULTS
  Poorly defined nodular opacities (P =.003), septal lines (P =.04), pleural effusion (P =.01), and adenopathy (P =.009) strongly correlated with a risk of clinical worsening with treatment. In six patients in group 1, postmortem examination of the lung revealed either pulmonary veno-occlusive disease or pulmonary capillary hemangiomatosis.
  
  
  CONCLUSIONS
  On pretherapeutic thin-section CT scans, poorly defined nodular opacities, septal lines, pleural effusion, and adenopathy should raise suspicion for pulmonary veno-occlusive disease or pulmonary capillary hemangiomatosis and provoke possible further evaluation before epoprostenol therapy.
authors.affiliation: Department of Radiology, Hôpital Antoine Béclère, 157 rue de la Porte de Trivaux, 92140 Clamart, France. arnaud.resten@abc.ap-hop-paris.fr
authors.forename: Arnaud
authors.initials: A
authors.lastname: Resten
authors.forename: Sophie
authors.initials: S
authors.lastname: Maître
authors.forename: Marc
authors.initials: M
authors.lastname: Humbert
authors.forename: Olivier
authors.initials: O
authors.lastname: Sitbon
authors.forename: Frédérique
authors.initials: F
authors.lastname: Capron
authors.forename: Gérald
authors.initials: G
authors.lastname: Simoneau
authors.forename: Dominique
authors.initials: D
authors.lastname: Musset
mesh_terms: D000328:Adult; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D011464:Epoprostenol / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006976:Hypertension, Pulmonary / Q000150:complications / Q000000981:diagnostic imaging* / Q000188:drug therapy; D008168:Lung / Q000000981:diagnostic imaging*; D008297:Male; D008875:Middle Aged; D010996:Pleural Effusion / Q000000981:diagnostic imaging / Q000209:etiology; D013902:Radiography, Thoracic; D012189:Retrospective Studies; D014057:Tomography, X-Ray Computed / Q000379:methods; D017211:Treatment Failure
chemical_list: D000959:Antihypertensive Agents; D011464:Epoprostenol